BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
65.35
+0.31 (0.48%)
Oct 9, 2026, 4:00 PM EDT - Market closed
BridgeBio Pharma Employees
As of June 30, 2026, BridgeBio Pharma had 1,003 total employees, including 999 full-time and 4 part-time employees. The number of employees increased by 164 or 19.55% since the number was reported on December 31, 2025. That makes BridgeBio Pharma the 14,838th largest employer in the world and 2,179th in the United States.
Employees
1,003
Change
164
Growth
19.55%
Revenue / Employee
$710,936
Profits / Employee
-$689,796
Market Cap
12.78B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1,003 | 164 | 19.55% | 999 | 4 |
| Dec 31, 2025 | 839 | 109 | 14.93% | 834 | 5 |
| Dec 31, 2024 | 730 | 174 | 31.29% | 725 | 5 |
| Dec 31, 2023 | 556 | 160 | 40.40% | 550 | 6 |
| Dec 31, 2022 | 396 | -182 | -31.49% | 392 | 4 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| ImmunityBio | 691 |
BBIO News
- 8 hours ago - BridgeBio Pharma presents results from Phase 3 CALIBRATE trial of encaleret - TheFly
- 4 days ago - BridgeBio Pharma price target lowered to $156 from $157 at Barclays - TheFly
- 5 days ago - BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 - GlobeNewsWire
- 5 days ago - BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting - GlobeNewsWire
- 5 days ago - BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA - TheFly
- 5 days ago - BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - GlobeNewsWire
- 6 days ago - BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day - GlobeNewsWire
- 6 days ago - BridgeBio Pharma presents new data from interim analysis of FORTIFY study - TheFly